ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Want to see ADCT full AI Analyst Report?
ADCT Stock Chart & Stats
$4.28
-$0.05(-2.50%)
At close: 4:00 PM EST
$4.28
-$0.05(-2.50%)
Day’s Range― - ―
52-Week Range$0.78 - $4.98
Previous CloseN/A
Volume185.04K
Average Volume (3M)2.46M
Market Cap
$133.55M
Enterprise Value$622.80M
Total Cash (Recent Filing)$231.01M
Total Debt (Recent Filing)$116.67M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Aug 11, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding127,191,154
10 Day Avg. Volume5,067,343
30 Day Avg. Volume2,457,276
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-2.41
Price to Sales (P/S)5.51
P/FCF Ratio-3.17
Enterprise Value/Market Cap4.66
Enterprise Value/Revenue7.87
Enterprise Value/Gross Profit8.67
Enterprise Value/Ebitda-7.49
Forecast
1Y Price Target
$5.67Price Target Upside32.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$80.79M
Bulls Say, Bears Say
Bulls Say
Commercial Product And Revenue TractionHaving an approved, revenue‑generating product (ZYNLONTA) provides a durable commercial foundation and validated go‑to‑market capability. Consistent product sales growth reduces binary program dependence, supports commercial infrastructure, and creates a base to scale lifecycle expansions and partner economics over multiple years.
Very High Gross MarginsExceptionally high gross margins indicate favorable unit economics for the ADC franchise, meaning incremental sales can contribute heavily to covering fixed costs and funding R&D. Over time high product margins improve the path to profitability as volumes increase or as new indications are commercialized.
Positive Phase 3 Confirmatory ResultsA positive Phase 3 readout is a structural inflection: it supports regulatory discussions, an sBLA pathway, and potential label expansion. That outcome materially strengthens the commercial and clinical value of ZYNLONTA, enabling compendia listing, broader prescribing and durable revenue upside if safety and approvals align.
Bears Say
Weak Balance Sheet / Negative EquityPersistent negative shareholders' equity and rising debt materially constrain financial flexibility and increase refinancing and covenant risk. Over months this reduces options for non‑dilutive funding, raises cost of capital, and may force dilutive financing or limit ability to invest in commercialization and development.
Ongoing Cash Burn And Negative Operating Cash FlowRepeated negative operating and free cash flow indicate structural cash burn requiring external capital to sustain operations. Even with runway into 2028, continued negative OCF risks dilution or reduced R&D/commercial spend if funding conditions tighten, challenging long‑term execution without successful approvals or partnerships.
Safety Signals In Pivotal TrialElevated serious and fatal adverse events in older patients pose a durable clinical and commercial risk: regulators or payers may demand label restrictions, additional studies, or risk‑management measures. Such constraints can narrow addressable patients, increase launch complexity, and depress long‑term uptake and reimbursement.
ADC Therapeutics News
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.78 and its highest was $4.98 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
ADC Therapeutics Ltd’s market cap is $133.55M.
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Aug 11, 2026 which is in 57 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on May 04, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.008.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -0.21.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 127,191,154 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -3.916%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Currently, no hedge funds are holding shares in ADCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.67 (32.40% Upside)
$5.67 (32.40% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.38%
12-Months-Change
Fundamentals
Return on Equity
65.27%
Trailing 12-Months
Asset Growth
6.96%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
ADCT Company Deck
ADCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced solid operational and financial execution (revenue growth ~15%, 13% reduction in adjusted operating expenses, improved GAAP and non-GAAP losses, and a cash runway into 2028) with near-term risks tied to clinical outcomes and ongoing cost reallocation (higher COGS and quarter-over-quarter cash decline). Management highlighted multiple upcoming data catalysts (LOTIS-5, LOTIS-7, IITs) that could materially drive future growth if positive, but outcome uncertainty and no expected 2026 revenue upside temper near-term outlook.View all ADCT earnings summariesADCT Stock 12 Month Forecast
Average Price Target
$5.67
▲(32.40% Upside)
Technical Analysis
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Olema Pharmaceuticals
―
Jade Biosciences
―
Ownership Overview
22.21% Insiders
6.03% Mutual Funds
40.43% Other Institutional Investors
27.21% Public Companies and
Individual Investors